Novartis AG stock performance trend indicates that the stock price has rallied 5.15% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -4.32% . Looking at the past 52 week period, the stock price is up at 3.95% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Novartis AG has a negative value of -2.7 compared to overall market performance.Novartis AG is having a Relative Strength Index of 61.23 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Novartis AG (NYSE:NVS) has tumbled 0.07% during the past week and has dropped 2.14% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.3%. Novartis AG (NYSE:NVS) has underperformed the index by 3.25% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Novartis AG (NYSE:NVS) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.12 points or 0.16% at $75.55 with 1,758,413 shares getting traded. Post opening the session at $75.75, the shares hit an intraday low of $75.55 and an intraday high of $75.98 and the price was in this range throughout the day. The company has a market cap of $179,360 million and the number of outstanding shares has been calculated to be 2,374,059,000 shares. The 52-week high of Novartis AG (NYSE:NVS) is $83.58 and the 52-week low is $66.93.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Novartis AG (ADR) was Initiated by Liberum to Buy on Mar 9, 2017. Novartis AG (ADR) was Upgraded by Societe Generale to Buy on Mar 8, 2017. Novartis AG (ADR) was Downgraded by Exane BNP Paribas to Underperform on Mar 7, 2017. Novartis AG (ADR) was Downgraded by Berenberg to Hold on Jan 17, 2017. Novartis AG (ADR) was Downgraded by Credit Suisse to Neutral on Jan 11, 2017.
Novartis AG (ADR) Last issued its quarterly earnings results on Jan 25, 2017. The company reported $1.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $1.12. The company had revenue of $12322.00 million for the quarter, compared to analysts expectations of $12440.65 million. The companys revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.12 EPS.
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.